ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $44.56 million. The enterprise value is $54.41 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 8.91 million shares outstanding. The number of shares has increased by 5.41% in one year.
| Current Share Class | 8.91M |
| Shares Outstanding | 8.91M |
| Shares Change (YoY) | +5.41% |
| Shares Change (QoQ) | +9.44% |
| Owned by Insiders (%) | 29.38% |
| Owned by Institutions (%) | 13.53% |
| Float | 5.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.48 |
| Forward PS | n/a |
| PB Ratio | 1.60 |
| P/TBV Ratio | 1.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.05 |
| EV / EBITDA | 52.10 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.59 |
| Debt / EBITDA | 14.87 |
| Debt / FCF | n/a |
| Interest Coverage | -3.12 |
Financial Efficiency
Return on equity (ROE) is -8.39% and return on invested capital (ROIC) is -2.45%.
| Return on Equity (ROE) | -8.39% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -2.45% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | $335,354 |
| Profits Per Employee | -$27,304 |
| Employee Count | 79 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ImmuCell has paid $10,000 in taxes.
| Income Tax | 10,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.94% in the last 52 weeks. The beta is 0.37, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +0.94% |
| 50-Day Moving Average | 5.10 |
| 200-Day Moving Average | 4.33 |
| Relative Strength Index (RSI) | 59.98 |
| Average Volume (20 Days) | 13,567 |
Short Selling Information
The latest short interest is 13,234, so 0.15% of the outstanding shares have been sold short.
| Short Interest | 13,234 |
| Short Previous Month | 17,128 |
| Short % of Shares Out | 0.15% |
| Short % of Float | 0.23% |
| Short Ratio (days to cover) | 0.23 |
Income Statement
In the last 12 months, ImmuCell had revenue of $26.49 million and -$2.16 million in losses. Loss per share was -$0.26.
| Revenue | 26.49M |
| Gross Profit | 7.94M |
| Operating Income | -1.64M |
| Pretax Income | -3.89M |
| Net Income | -2.16M |
| EBITDA | 1.04M |
| EBIT | -1.64M |
| Loss Per Share | -$0.26 |
Full Income StatementBalance Sheet
The company has $3.81 million in cash and $15.53 million in debt, giving a net cash position of -$11.72 million or -$1.32 per share.
| Cash & Cash Equivalents | 3.81M |
| Total Debt | 15.53M |
| Net Cash | -11.72M |
| Net Cash Per Share | -$1.32 |
| Equity (Book Value) | 26.41M |
| Book Value Per Share | 2.99 |
| Working Capital | n/a |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 29.97%, with operating and profit margins of -6.19% and -8.14%.
| Gross Margin | 29.97% |
| Operating Margin | -6.19% |
| Pretax Margin | -8.10% |
| Profit Margin | -8.14% |
| EBITDA Margin | 3.94% |
| EBIT Margin | -6.19% |
| FCF Margin | n/a |